Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas

In a phase II study, 32 patients with advanced pancreatic carcinoma were treated with intravenous 6-thioguanine. A 30-min infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the course being repeated every 5 weeks. A median of two courses (range, 1-10) was admini...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1991-11, Vol.9 (4), p.369-371
Main Authors: AJANI, J. A, PAZDUR, R, WINN, R. J, ABBRUZZESE, J. L, LEVIN, B, BELT, R, YOUNG, J, PATT, Y. Z, KRAKOFF, I. H
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Drug Administration Schedule
Drug Evaluation
Female
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Pancreatic Neoplasms - drug therapy
Pharmacology. Drug treatments
Thioguanine - administration & dosage
Thioguanine - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a phase II study, 32 patients with advanced pancreatic carcinoma were treated with intravenous 6-thioguanine. A 30-min infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the course being repeated every 5 weeks. A median of two courses (range, 1-10) was administered. Among the 32 patients, 30 having measurable cancer and optimum follow-up were fully assessable for response. One patient achieved a partial response of extensive liver metastases (12+ months), and another patient had a transient minor response (5 weeks). Cancer in 27 of 30 assessable patients progressed during intravenous 6-thioguanine treatment. Myelosuppression, although frequent, was mild to moderate at these doses and did not result in significant morbidity. Nonhematologic toxicities were also mild. Our data suggest that intravenous 6-thioguanine given at this schedule is ineffective in previously untreated patients with advanced carcinoma of the pancreas.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00183584